PDCD1 and non-small cell lung carcinoma: Therapeutic blockage of the PD-1/PD-L1 checkpoint has proven significant clinical benefit in many advanced solid malignancies like melanoma and non-small cell lung cancers and opened a new era of precision cancer medicine [10,11,12].